Bill that cuts foreign aid and public broadcasting heads to Trump's desk
The bill, which will see the government cut $9bn (£6.7bn) in total, was passed in a 216 to 213 vote just hours after midnight on Friday. All Democrats and only two Republicans voted against the cuts.
The US Senate passed its version of the bill less than 24 hours earlier.
The bill now heads to President Donald Trump's desk to be signed into law. "THIS IS BIG!!!", he wrote on social media after the vote.
Republicans have said the rescissions package, a political tool to cut funding already approved by Congress, is likely to be the first of many.
"This isn't the end, it's the beginning," House Speaker Mike Johnson said after the bill was passed.
The victory for Republicans and President Trump is the latest development in their ongoing effort to shrink government spending.
"Nine billion dollars is a good start," House Majority Leader Steve Scalise said.
The approved funding cuts include large reductions to the Corporation for Public Broadcasting, which includes PBS and NPR.
It also includes cuts to the US Agency for International Development (USAID), the largest US global humanitarian programme.
The spending cuts, however, were slightly smaller than Trump had originally proposed. In the Senate version of the bill, lawmakers voted to keep $400m in the budget for Pepfar, a global Aids prevention programme, bringing the proposed cuts from $9.4bn to $9bn.
The bill faced a bit of a rocky path on its way through the House and Senate, with lawmakers on both sides of the isle wary of cuts to foreign aid and public broadcasting.
On the day the Senate passed its version of the bill, people in Alaska were told to tune into their local radio station that includes NPR programming after an earthquake that struck off the coast prompted tsunami warnings.
"Public radio is a lifeline, connecting rural communities to the rest of the nation, and providing life-saving emergency broadcasting and weather alerts. It cannot be replaced," NPR President Katherine Maher said after the Senate passed the bill.
According to US media, this rescissions package was the first to succeed in over 30 years.
US Senate approves $9bn cuts to foreign aid and public broadcasting funds
How Trump public broadcasting cuts could hit rural America
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Key Market Players Paving the Way for Advancements in Exosome-Based Diagnostics and Therapeutics
The global exosome research market is anticipated to expand from USD 214.4 million in 2025 to USD 480.6 million by 2030, at a CAGR of 17.5%. This growth is driven by the rising need for advanced diagnostics due to the prevalence of chronic diseases like cancer and neurodegenerative disorders. Exosomes, serving as biomarkers and therapeutic delivery agents, fulfill this demand. The kits & reagents segment is expected to lead growth, aligning with the increased demand for efficient exosome research tools. North America is projected to experience the highest growth, thanks to significant government investments supporting research initiatives. Key players such as Thermo Fisher Scientific and Bio-Techne are profiled. Exosome Research Market Dublin, July 18, 2025 (GLOBE NEWSWIRE) -- The "Exosome Research Market by Offering (Kits, Reagents (Antibodies, Isolation, Purification), Instruments, Services), Indication (Cancer, Infectious Diseases), Application (Biomarkers, Vaccines), Manufacturing Services (Stem Cell) - Global Forecast to 2030" report has been added to global exosome research market is projected to reach USD 480.6 million by 2030 from USD 214.4 million in 2025, at a CAGR of 17.5% during the forecast period. The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the overall exosome research market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges. The expansion of the exosome research market is primarily fueled by the escalating incidence of chronic diseases, including cancer, neurodegenerative disorders, and CVDs; this trend underscores the urgent need for novel diagnostic and therapeutic strategies. Exosomes, due to their properties as potential biomarkers and their capacity to facilitate targeted therapeutic delivery, are uniquely positioned to address the increasing demand for advanced disease diagnostics and treatment modalities. The kits & reagents segment is expected to grow at the highest CAGR during the study academic institutions, biotechnology companies, and diagnostic developers delve deeper into the multifaceted roles of exosomes in disease diagnostics and therapeutic interventions, there has been a notable increase in the demand for standardized, user-friendly kits & reagents. These specialized tools play a crucial role in simplifying and expediting the workflows associated with exosome isolation, purification, labeling, and downstream analysis. Exosomes, nano-sized vesicles secreted by cells, have emerged as significant biomarkers in various diseases, necessitating precise handling and standardization offered by commercially available kits helps ensure that researchers can perform these tasks with consistency and reliability, which is vital in both translational research and preclinical development. In particular, reproducibility is critical in scientific research; utilizing validated kits ensures consistent protocols that minimize variability and enhance overall research outcomes. This reliability is particularly pertinent in biomarker discovery and liquid biopsy research, where the identification of accurate biomarkers is paramount for early disease detection and the growing interest in exosome-based diagnostics - especially within oncology for cancer detection and neurodegenerative diseases like Alzheimer's and Parkinson's - laboratories are increasingly opting for ready-to-use reagent systems. These systems facilitate sample preparation, RNA and DNA extraction, and comprehensive cargo profiling, thereby supporting a range of downstream molecular applications. The integration of such standardized tools not only streamlines the research process but also enhances the quality of data generated, ultimately contributing to the advancement of exosome research in clinical settings. As the landscape of diagnostics continues to evolve, the role of such reliable and efficient kits will become even more pronounced, paving the way for breakthroughs in personalized medicine and targeted America is expected to grow at the highest CAGR in the global exosome research market from 2025 to America maintains its leading position in the global exosome research market, primarily due to substantial government investment and support mechanisms. Key organizations such as the National Institutes of Health (NIH) in the United States are pivotal, channeling significant funding into biomedical research, specifically targeting projects centered on exosomes. This financial endorsement empowers researchers to explore novel applications of exosomes in both diagnostics and therapeutics. For example, in June 2024, the National Heart, Lung, and Blood Institute (NHLBI) renewed a USD 12 million Program Project Grant (PPG) to support researchers at the Lewis Katz School of Medicine at Temple investigation focuses on heart cell-derived exosomes and their involvement in cardiac injury and repair processes. This funding facilitates a deeper understanding of the mechanisms by which exosomes contribute to myocardial tissue regeneration, potentially leading to groundbreaking therapeutic strategies. Likewise, in August 2023, the National Cancer Institute (NCI) allocated USD 2.5 million to the Sylvester Comprehensive Cancer Center to advance research on exosome-based biomarkers for prostate cancer detection through urine and blood assays. Such robust government backing not only propels scientific exploration but also fosters collaboration between academic institutions and industry, thereby cultivating a dynamic research ecosystem. This well-capitalized environment accelerates innovation and reinforces North America's status as a frontrunner in exosome research. As a result, the region continues to draw in investments and talent, driving ongoing growth within the exosome research report provides insights on the following pointers: Analysis of key drivers (increasing investment in pharmaceutical & life sciences research, rising cancer prevalence, and increasing interest in exosome-based procedures), restraints (technical complexity of exosome isolation, and regulatory uncertainty in exosome research), opportunities (rising investments in emerging countries for exosome research, growing interest in exosome-based therapeutics, and increasing demand for personalized medicines), and Challenges (lack of gold standard protocols for exosome development and production and limited understanding of cargo loading). Product Development/Innovation: Detailed insights on upcoming products, research and development activities, and new product approvals/launches in the exosome research market. Market Development: Comprehensive information about lucrative markets; the report analyses the market across varied regions. Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the exosome research market. Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the exosome research market. Key Attributes: Report Attribute Details No. of Pages 325 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $214.4 Million Forecasted Market Value (USD) by 2030 $480.6 Million Compound Annual Growth Rate 17.5% Regions Covered Global Companies Featured Thermo Fisher Scientific Inc. Qiagen Lonza Danaher Bio-Techne System Biosciences, LLC Amsbio Roosterbio, Inc. Miltenyi Biotec Norgen Biotek Corp. Aethlon Medical, Inc. Creative Medical Technologies Holdings, Inc. Spectris Nanofcm, Inc. Izon Science Limited Capricor Therapeutics, Inc. Anjarium Biosciences AG Ciloa Innovaprep Ilias Biologics Inc. Unchained Labs Rion Inc. Cell Guidance System LLC Inoviq Nx Pharmagen Exopharm Everzom Nanosomix Creative Biolabs For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Exosome Research Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
8 minutes ago
- Yahoo
Abbott Laboratories (ABT) Drops on Lower Full-Year Guidance
We recently published . Abbott Laboratories (NYSE:ABT) is one of the worst-performing companies on Thursday. Abbott Laboratories declined by 8.52 percent on Thursday to end at $120.51 apiece as investors were disheartened by the lowering of its full-year guidance. For the full year, Abbott Laboratories (NYSE:ABT) now projects organic sales growth, excluding COVID-19 testing-related sales, to grow between 7.5 to 8 percent, or 6 to 7 percent when including COVID-19 testing-related sales. Adjusted diluted earnings per share were pegged at $5.1 to $5.2 for the full year, while adjusted diluted EPS were expected to settle at $1.28 to $1.32 for the third quarter of the year. In an interview on CNBC, Abbott Laboratories (NYSE:ABT) CEO Robert Ford deemed the drop an 'overreaction.' 'I think this is a little bit of an overreaction. Of course, we are all over this,' Ford said. 'We're focused on this, but the fundamentals of the entire rest of the company are pretty much intact, and this is just really a point in time that we have to get through.' An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. In the second quarter of the year, Abbott Laboratories (NYSE:ABT) grew its net income by 36.7 percent to $1.779 billion from $1.3 billion in the same period last year. Net sales increased by 7.4 percent to $11.142 billion from $10.377 billion year-on-year. While we acknowledge the potential of ABT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
8 minutes ago
- Yahoo
Technetium-99m Market Size to Reach USD 6.29 Billion by 2031, Growing at a CAGR of 3.9%
NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global technetium-99m market is witnessing substantial growth with the surging prevalence of chronic diseases and advancements in nuclear imaging techniques. The technetium-99m market is expected to reach US$6.29 billion by 2031 from US$ 4.61 billion in 2024; it is anticipated to register a CAGR of 3.9% during the forecast period. Technetium-99m (Tc-99m) is an extensively used radioactive isotope for diagnostic imaging in nuclear medicine. It holds the position of being the most common medical radioisotope worldwide and is used for over 40,000 imaging procedures daily in the US. To explore the valuable insights in the Technetium-99m Market report, you can easily download a sample PDF of the report - Some of the reasons behind Tc-99m's medical popularity are its ideal imaging properties, such as a short half-life of about six hours, suitable gamma energy, as well as providing a low radiation dose, giving it the capability to image organs such as the brain, heart, bones, lungs, kidneys, thyroid, and liver. The development of this market is sustained by increasing demand for Tc-99m-based radiopharmaceuticals in cardiovascular imaging and cancer detection, along with other clinical applications. North America stands as a huge market due to the advanced healthcare infrastructure and high rate of chronic diseases. Asia Pacific is growing fast owing to healthcare infrastructure investments and a focus on advanced diagnostics. The report carries an in-depth analysis of market trends, key players, and future opportunities. The technetium-99m market study focuses on an array of technologies that are expected to fuel the demand in the coming years. For Detailed Technetium-99m Market Insights, Visit: Overview of Report Findings Increasing Chronic Diseases Prevalence: The increase in prevalence of chronic diseases is a much stronger driver for the global Technetium-99m (Tc-99m) market. Tc-99m is the most important radioisotope used in more than 80% of nuclear medicine procedures in the world, mostly used in SPECT scanning for the diagnosis of cancer, cardiovascular diseases, and neurological disorders. According to the International Agency for Research on Cancer, the prevalence of cancer is high worldwide. It is estimated that there were 19.3 million cancer cases globally in 2020, and the number is expected to reach ~30.2 million by 2040. With an increase in the incidence of chronic diseases due to aging populations, sedentary lifestyles, and poor dietary habits, the demand for higher diagnostic imaging techniques rises correspondingly. Such a scenario is evident in Asia Pacific, where chronic diseases such as diabetes and cardiovascular diseases are rising. Health care providers are thus increasingly adopting technetium-based imaging techniques for early diagnosis and for planning of treatment. This rise in demand is favoring the development of the Tc-99m market. Soaring Technological Advancements: Technological discoveries open a whole new set of vistas for the Technetium-99m (Tc-99m) market by making nuclear imaging more efficient, accurate, and accessible. At the forefront of these discoveries are radiopharmaceutical production technologies that include cyclotron-based Tc-99m production that nullifies the need for assessing the aged nuclear reactors and thereby assures more stable Tc-99m supplies. In addition, imaging instrument improvement, mainly within SPECT and hybrid imaging equipment such as SPECT/CT, have increased the resolution and diagnostic ability, thereby increasing Tc-99m's clinical utility. Further, automation in radiopharmacy and simultaneous integration of digital imaging workflows minimize human errors and maximize safety and efficiency. Artificial intelligence and machine learning are further being explored and used for image analysis to provide enhanced and more rapid diagnostic capabilities. Thus, these technological advancements account for the expanding sphere of clinical applications of Tc-99m while reducing operational costs in nuclear medicine, which include its accessibility to emerging markets. Several innovations and various avenues for research, investment, and patient care are being formed in the Tc-99m market. Stay Updated on The Latest Technetium-99m Market Trends: Geographical Insights: In 2024, North America led the technetium-99m market with a substantial revenue share, followed by Europe and Asia Pacific. Further, Asia Pacific is expected to register the highest CAGR during the forecast period. Market Segmentation By application, the market is categorized into cardiovascular, bone scan, respiratory, tumor imaging, and others. The bone scan segment accounted for the largest share of the market in 2024. Based on end user, the market is segmented into hospitals, diagnostic and imaging centers, and others. The hospitals segment held the largest share of the market in 2024. The technetium-99m market is segmented into five major regions: North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America. Competitive Strategy and Development Key Players: Lantheus Medical Imaging Inc., Curium, Jubilant Pharma Company, NorthStar Medical Radioisotopes LLC, Sun Pharmaceutical Industries Inc., Advancing Nuclear Medicine, NTP Radioisotopes SOC Ltd, Northwest Medical Isotopes LLC, and SHINE Technologies LLC are major companies operating in the market. Trending Topics: Emergence of Hybrid Imaging Techniques, Advancements in Radiopharmaceutical Development, and Sustainability and Cost-Effectiveness Initiatives. Purchase Premium Copy of Global Technetium-99m Market Size and Growth Report (2021-2031) at: Global Headlines on Technetium-99m Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScan (Kit for the Preparation of Technetium Tc 99m Succimer Injection). BWXT Medical and Laurentis Complete Key Tc-99m Generator Program Milestone. IAEA Launches Research Project to Develop New Technetium-99m Radiopharmaceuticals. Conclusion The demand for technetium-99m is expanding at a rapid pace with increasing requirements for advanced diagnostic imaging, primarily for areas such as oncology, cardiology, and neurology. The largest market for Technetium-99m is North America followed by the easy availability of radiopharmaceuticals and higher average cost of kit for Tc-99m. The technetium-99m market in Asia Pacific is segmented into Japan, China, and India and is also expected to grow at the fastest CAGR due to the increasing investments in improving healthcare infrastructure and rising focus on advanced diagnostics. The development of imaging, such as SPECT and hybrid SPECT/CT systems, is becoming more accurate and reliable in Tc-99m using diagnostics. Furthermore, ongoing development of production technologies, such as non-reactor-based ones address Mo-99 supply chain issues, the progenitor isotope for Tc-99m. Thus, continuous advancements in imaging instruments and manufacturing technologies and government initiatives for bettering nuclear medication facilities are expected to drive the market during the forecast period. The report from The Insight Partners lists several stakeholders—including radiopharmaceutical manufacturers, medical equipment suppliers, healthcare providers, and regulatory bodies—along with valuable insights to navigate this evolving market landscape and unlock new opportunities successfully. For More Latest Life Sciences Research Reports & Industry Analysis - Trending Related Reports: Bone Scan Market Growth, Top Key Players, and Regional Forecast by 2031 Respiratory Disposable Devices Market Size, Trends, Shares, and Forecast – 2031 Respiratory Medical Device Market Size, Trends, Shares, and Forecast – 2031 Respiratory Drug Delivery Devices Market Size, Trends, Shares, and Forecast - 2031 The Tumor Embolization Market Size is expected to register a CAGR of 8.9% from 2025 to 2031 The Heart Tumor Market Size is expected to register a CAGR of 8.0% from 2025 to 2031 The Tumor Ablation Market Size is expected to register a CAGR of 12.5% from 2025 to 2031 The Respiratory Protection Equipment Market Size is expected to register a CAGR of 6.8% from 2025 to 2031 Respiratory Medical Device Professional Market Size Drivers, Opportunities, Trends, and Forecasts by 2031 About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Ankit Mathur E-mail: Phone: +1-646-491-9876 Press Release - Logo - View original content: SOURCE The Insight Partners Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data